Physician profile
Charles D Williams
NPI 1346256385
$10,358.38
in general payments reported to CMS, 2019-2025
45 companies · $743 in 2025
The $743 reported for 2025 was more than what 80% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,196 · 2020: $1,558 · 2021: $2,008 · 2022: $1,682 · 2023: $1,022 · 2024: $1,150 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,906 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,906.37 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,870.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,126.66 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $832.50 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $832.34 | 2019-2023 | |
| Abbvie INC. | $782.56 | 2019-2025 | Ubrelvy, Vraylar |
| Pfizer INC. | $663.54 | 2019-2025 | |
| Lilly USA, LLC | $647.53 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $455.15 | 2019-2025 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $360.85 | 2019-2025 | Steglatro, Belsomra, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.34 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $287.51 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $207.44 | 2022 | |
| Sanofi-Aventis U.S. LLC | $160.33 | 2020-2025 | |
| Boston Scientific Corporation | $138.38 | 2019-2025 | General - Pain Management |
| Astellas Pharma US INC | $131.71 | 2024-2025 | Veozah |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.